Chronic Spontaneous Urticaria Clinical Trial
Official title:
Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)
This study aims to investigate the influence of psychosocial factors on Chronic Spontaneous Urticaria (CSU). Preliminary research suggests a potential link between stress and the experience of CSU symptoms. In light of these findings, our study offers a stress management intervention for individuals diagnosed with CSU. The intervention consists of a 6-week online course designed to cultivate effective stress management techniques, referred to as 'attention-based training (ABT).' The course asks each participant to develop their own ABT practice, along with a one-hour session per week, providing techniques that participants can use to combat stressors related to their condition.
Chronic Spontaneous Urticaria (CSU) is a common disorder that is poorly understood and frequently misdiagnosed. The burden of the disease can include stress, anxiety, sleep disturbances, and difficulty with activities of daily living. Furthermore, psychological difficulties such as stress, may also aggravate the symptomatic burden of CSU. Holistic interventions are used as a complementary approach to alleviate symptoms in chronic diseases and may represent a valuable non-pharmacological approach in CSU. In 2021, Dr Padraic Dunne and colleagues published a feasibility assessment of an 8 week attention-based training programme to aid in the management of CSU [1]. Whilst this trial was deemed feasible and valuable for participants involved, further research was required with a wider sample to determine the role ABT may have in the management of the condition. List of Aims and Objectives This current research aims to expand on their pilot study, and provide an evidence based non-pharmacological intervention to aid those in their management of CSU. This project will be the one of the first to provide CSU patients with a psychological intervention in conjunction with their clinical treatment. We believe that a combination of non-pharmacological and pharmacological solutions will ease the suffering caused by this condition and reduce the physical and fiscal burden on the Irish Health service and related clinics. This study will 1.) Aim to identify the current psychosocial baseline of CSU patients attending urticarial clinics in Ireland and Scotland, to further highlight the psychosocial experience of this population. 2.) Provide and assess the effectiveness of an 6 week ABT programme for CSU management and patient wellbeing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06077773 -
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
|
Phase 2 | |
Completed |
NCT04538794 -
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
|
Phase 1 | |
Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05298215 -
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria
|
Phase 2 | |
Terminated |
NCT04612725 -
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
|
Phase 2 | |
Terminated |
NCT05528861 -
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
|
Phase 2 | |
Completed |
NCT04109313 -
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
|
Phase 2 | |
Completed |
NCT03580356 -
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
|
Phase 3 | |
Completed |
NCT03580369 -
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
|
Phase 3 | |
Completed |
NCT05030311 -
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
|
Phase 3 | |
Recruiting |
NCT06162728 -
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
|
Phase 1/Phase 2 | |
Completed |
NCT05107115 -
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
|
Phase 2 | |
Recruiting |
NCT06042478 -
A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.
|
Phase 3 | |
Terminated |
NCT04159701 -
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Completed |
NCT03749135 -
Dupilumab in Chronic Spontaneous Urticaria
|
Phase 2 | |
Not yet recruiting |
NCT06396026 -
A Study of Efficacy and Safety of TLL-018 in CSU Participants
|
Phase 3 | |
Completed |
NCT02649218 -
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
|
Phase 2 | |
Active, not recruiting |
NCT05368285 -
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
|
Phase 2 | |
Completed |
NCT05373355 -
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
|
Phase 1 | |
Not yet recruiting |
NCT06365879 -
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
|
Phase 3 |